Tabula Rasa HealthCare (TRHC) Downgraded by ValuEngine

ValuEngine cut shares of Tabula Rasa HealthCare (NASDAQ:TRHC) from a buy rating to a hold rating in a report published on Monday morning, ValuEngine reports.

A number of other equities analysts have also issued reports on the stock. Cantor Fitzgerald reiterated a buy rating and issued a $99.00 target price on shares of Tabula Rasa HealthCare in a research report on Monday. Piper Jaffray Companies increased their target price on shares of Tabula Rasa HealthCare from $73.00 to $78.00 and gave the company an overweight rating in a research report on Thursday, May 9th. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a strong-buy rating to a hold rating in a research report on Wednesday, May 8th. BidaskClub upgraded shares of Tabula Rasa HealthCare from a sell rating to a hold rating in a research report on Tuesday, May 7th. Finally, Guggenheim assumed coverage on shares of Tabula Rasa HealthCare in a research report on Wednesday, April 17th. They issued a neutral rating and a $58.00 target price for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of Buy and a consensus price target of $80.53.

Shares of TRHC opened at $46.46 on Monday. The stock has a market capitalization of $1.05 billion, a P/E ratio of 136.65 and a beta of 1.51. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.80 and a quick ratio of 1.73. Tabula Rasa HealthCare has a 52-week low of $42.29 and a 52-week high of $91.16.

Tabula Rasa HealthCare (NASDAQ:TRHC) last announced its earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.14). The firm had revenue of $60.96 million during the quarter, compared to analyst estimates of $59.24 million. Tabula Rasa HealthCare had a negative net margin of 18.15% and a positive return on equity of 4.22%. Equities research analysts expect that Tabula Rasa HealthCare will post -0.63 EPS for the current fiscal year.

In other news, CEO Calvin H. Knowlton sold 8,270 shares of the firm’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total transaction of $443,933.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Orsula V. Knowlton sold 8,000 shares of the firm’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $57.02, for a total transaction of $456,160.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,270 shares of company stock valued at $2,645,294. Insiders own 14.00% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Eqis Capital Management Inc. boosted its position in shares of Tabula Rasa HealthCare by 3.2% during the 4th quarter. Eqis Capital Management Inc. now owns 6,156 shares of the company’s stock valued at $392,000 after purchasing an additional 193 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in Tabula Rasa HealthCare by 3.0% during the first quarter. Louisiana State Employees Retirement System now owns 6,600 shares of the company’s stock valued at $372,000 after buying an additional 193 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Tabula Rasa HealthCare by 3.3% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,019 shares of the company’s stock valued at $340,000 after buying an additional 194 shares in the last quarter. State of Alaska Department of Revenue lifted its stake in Tabula Rasa HealthCare by 4.2% during the fourth quarter. State of Alaska Department of Revenue now owns 5,676 shares of the company’s stock valued at $361,000 after buying an additional 231 shares in the last quarter. Finally, Comerica Bank lifted its stake in Tabula Rasa HealthCare by 1.4% during the fourth quarter. Comerica Bank now owns 16,519 shares of the company’s stock valued at $934,000 after buying an additional 235 shares in the last quarter. Institutional investors own 76.85% of the company’s stock.

Tabula Rasa HealthCare Company Profile

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

See Also: Insider Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.